01 / SOURCE
European deal flow
Partnerships across Europe and the Middle East surface healthtech founders before broader networks see them. We get first-look on clinically validated, regulatory-aware teams.
From sickcare to healthcare.
European
deal-by-deal
Healthtech VC.
We source, structure, and co-invest in healthtech rounds alongside business angels, family offices, and corporate partners. One deal at a time. European, since 2014.
Never a blind pool. Each opportunity stands alone: investors review the deal, subscribe to a dedicated SPV, and receive every disclosure document before they commit.
From sickcare to healthcareRemote monitoringDetection and diagnosisPersonalised medicineFrom sickcare to healthcareRemote monitoringDetection and diagnosisPersonalised medicineFrom sickcare to healthcareRemote monitoringDetection and diagnosisPersonalised medicine
Approach
Source, structure, support.
Our partnership network across Europe and the Middle East surfaces healthtech founders at source. Each round runs through a dedicated SPV. The investor community is itself the support layer: healthcare experts review the diligence and back the teams they choose.
02 / STRUCTURE
Bespoke SPVs, deal-by-deal
Each financing round runs through a dedicated SPV, regulated or unregulated as the deal requires. Investors back the specific opportunities that fit their thesis, on the same disclosure standard every time.
03 / SUPPORT
Smart money, not just money
The investor community brings healthcare expertise back to the founder: operational know-how, regulatory insight, commercial introductions. The path from validation to clinical adoption gets shorter.
Why deal-by-deal
No blind pool. Ever.
High Conviction over Spray & Pray.
Traditional venture funds ask investors to commit capital up front, then deploy it over years into deals the investor never sees individually. The structure suits the fund, not the backer.
We don't do that. Every Aescuvest opportunity is its own SPV. Its own term sheet. Its own diligence pack. Its own decision. You see the company. You see the round. You decide whether to participate. The same depth of diligence runs on every deal regardless of cheque size.
Selected investments
A few of the companies we've backed.
A handful of the healthtech companies we've financed through our SPVs across remote monitoring, detection and diagnosis, and personalised medicine. Not all of them.
- Remote monitoring
- Detection and diagnosis
- Personalised medicine
Remote monitoringJerusalem, IL
Neteera Technologies
Contactless, continuous vital-sign monitoring using sub-THz radar. Clinic-grade data, wherever a patient sits.
Detection and diagnosisBerlin, DE
DiaMonTech
Non-invasive blood-glucose monitoring via mid-infrared spectroscopy. No needle. No consumable.
Personalised medicineMunich, DE
neurocare group
Personalised mental-health treatment platform for clinicians, combining digital diagnostics with stimulation therapies.
Detection and diagnosisTel Aviv, IL
Scopio Labs
Full-field digital cell morphology. AI-assisted hematology that replaces the manual microscope review.
Detection and diagnosisVienna, AT
piur imaging
Tomographic 3D ultrasound for early vascular and thyroid disease. Lifts ultrasound out of operator dependence.
Personalised medicineBerlin, DE
Lillian Care
Primary care for underserved rural regions. Telemedicine plus an on-site medical assistant.
Portfolio metadata drawn from public sources. Detailed information on individual deals is shared with prospective investors under NDA.
Process
How an opportunity moves from inbox to SPV.
The same routine on every round. Cheque size and sector do not change it.
- 01
Sourcing
Partner networks, portfolio referrals, and direct founder relationships. We do not run a pitch competition.
- 02
Screening
Sector fit, regulatory pathway, founding team, capital efficiency. Most teams are politely declined at this stage.
- 03
Diligence
Clinical, IP, regulatory, financial — accelerated by Acelia, our AI diligence copilot. Independent expert reviewers from our investor community add domain depth the firm alone could not.
- 04
Structuring
SPV setup, term-sheet negotiation, lead-investor coordination. Investors commit deal-by-deal. No blind-pool exposure. Terms in writing.
- 05
Support
Active board engagement, regulatory navigation, follow-on coordination. We stay hands-on through to exit, not just through to wire transfer.
For qualified investors
Four kinds of co-investor.
Aescuvest is open to qualified investors as defined under the relevant EU regulation. Onboarding, KYC, and AML checks run before any commitment.
Most common
Business Angels
Single-deal participation through an SPV. Co-invest alongside healthcare experts you know by name, on terms you reviewed before you subscribed.
HNWIs
Build a curated portfolio across themes at a pace that fits your conviction. Pick the deals that match your thesis, skip the ones that do not.
Family Offices
Allocator-grade reporting, custom mandates, anchor positions on lead deals. Direct line to the Investment Committee on any deal in diligence.
Corporate Investors
Exposure aligned to your therapeutic or technology areas. Co-development structures available when both sides see the fit.
FAQ
Questions investors ask before joining.
Who can invest with Aescuvest?
Qualified investors as defined under the relevant EU regulation: business angels, HNWIs, family offices, and corporate investors. KYC and AML onboarding runs before any subscription.
How does the SPV structure work?
For each deal we set up a dedicated Special Purpose Vehicle. Investors subscribe to the SPV, which then invests in the portfolio company. This bundles voting rights, simplifies cap-table management for the founder, and standardises legal terms across deals.
How do I see and access my investments?
Existing investors access their subscriptions, legal documents, and reporting through our investor portal on bunch.capital. The portal handles each SPV individually. Deal documentation is delivered before subscription and remains accessible afterwards.
What sectors do you focus on?
Healthtech, exclusively, across remote monitoring, detection and diagnosis, and personalised medicine. We do not invest in pure biotech drug development, in healthcare services, or in software unrelated to clinical outcomes.
How are fees and carry structured?
A management fee on committed SPV capital plus carried interest on profits. Fees are disclosed per deal in the SPV documentation before any commitment. Aescuvest co-invests in every round.
What is the typical horizon to liquidity?
Healthtech is patient capital. Realistic exit horizons run several years for early-stage rounds and shorter for later-stage approvals-track investments. Some portfolio companies pay interim dividends. Most do not.
For founders
If you're building healthtech, apply directly.
We review applications through aescuvest.app, our AI-assisted deal-flow platform. Intake, scoring, and the first round of diligence run on the platform, so every team gets a fast, honest read. If we want to move forward, a partner reaches out soon after submission.
Applications are reviewed in batches. We commit to a substantive reply on every submission, accepted or declined.
Application flowaescuvest.app
- 01
Intake
Structured questionnaire. Clinical, IP, regulatory, financial.
- 02
Pre-screen
Sector fit, capital efficiency, founding team.
- 03
Partner review
If we move forward, a partner reaches out directly.
Representation. Not a screenshot.
Two paths
Two ways to engage with Aescuvest.
Capital
Become a co-investor
Get in touch and we will walk you through how the SPV process works, what is currently in the pipeline, and whether your thesis fits ours.
Capital seeker
Apply for funding
Healthtech founders, clinical-stage onwards. The application is short and direct. We reply on every submission.